Ferket Bart S, van Kempen Bob J H, Hunink M G Myriam, Agarwal Isha, Kavousi Maryam, Franco Oscar H, Steyerberg Ewout W, Max Wendy, Fleischmann Kirsten E
Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands ; Department of Radiology, Erasmus MC, Rotterdam, the Netherlands.
Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands ; Department of Radiology, Erasmus MC, Rotterdam, the Netherlands ; Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America.
PLoS One. 2014 Feb 18;9(2):e88312. doi: 10.1371/journal.pone.0088312. eCollection 2014.
According to population-based cohort studies CT coronary calcium score (CTCS), carotid intima-media thickness (cIMT), high-sensitivity C- reactive protein (CRP), and ankle-brachial index (ABI) are promising novel risk markers for improving cardiovascular risk assessment. Their impact in the U.S. general population is however uncertain. Our aim was to estimate the predictive value of four novel cardiovascular risk markers for the U.S. general population.
Risk profiles, CRP and ABI data of 3,736 asymptomatic subjects aged 40 or older from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 exam were used along with predicted CTCS and cIMT values. For each subject, we calculated 10-year cardiovascular risks with and without each risk marker. Event rates adjusted for competing risks were obtained by microsimulation. We assessed the impact of updated 10-year risk scores by reclassification and C-statistics. In the study population (mean age 56±11 years, 48% male), 70% (80%) were at low (<10%), 19% (14%) at intermediate (≥10-<20%), and 11% (6%) at high (≥20%) 10-year CVD (CHD) risk. Net reclassification improvement was highest after updating 10-year CVD risk with CTCS: 0.10 (95%CI 0.02-0.19). The C-statistic for 10-year CVD risk increased from 0.82 by 0.02 (95%CI 0.01-0.03) with CTCS. Reclassification occurred most often in those at intermediate risk: with CTCS, 36% (38%) moved to low and 22% (30%) to high CVD (CHD) risk. Improvements with other novel risk markers were limited.
Only CTCS appeared to have significant incremental predictive value in the U.S. general population, especially in those at intermediate risk. In future research, cost-effectiveness analyses should be considered for evaluating novel cardiovascular risk assessment strategies.
根据基于人群的队列研究,冠状动脉CT钙化评分(CTCS)、颈动脉内膜中层厚度(cIMT)、高敏C反应蛋白(CRP)和踝臂指数(ABI)是有望改善心血管风险评估的新型风险标志物。然而,它们在美国普通人群中的影响尚不确定。我们的目的是评估这四种新型心血管风险标志物对美国普通人群的预测价值。
使用了2003 - 2004年国家健康与营养检查调查(NHANES)中3736名40岁及以上无症状受试者的风险概况、CRP和ABI数据,以及预测的CTCS和cIMT值。对于每个受试者,我们计算了包含和不包含每种风险标志物的10年心血管风险。通过微观模拟获得针对竞争风险调整后的事件发生率。我们通过重新分类和C统计量评估更新后的10年风险评分的影响。在研究人群(平均年龄56±11岁,48%为男性)中,70%(80%)的人10年心血管疾病(冠心病)风险较低(<10%),19%(14%)的人处于中等风险(≥10 - <20%),11%(6%)的人处于高风险(≥20%)。使用CTCS更新10年心血管疾病风险后,净重新分类改善最高:0.10(95%置信区间0.02 - 0.19)。使用CTCS时,10年心血管疾病风险的C统计量从0.82增加了0.02(95%置信区间0.01 - 0.03)。重新分类最常发生在中等风险人群中:使用CTCS时,36%(38%)的人转移到低风险,22%(30%)的人转移到高心血管疾病(冠心病)风险。其他新型风险标志物的改善有限。
在美国普通人群中,只有CTCS似乎具有显著的增量预测价值,尤其是在中等风险人群中。在未来的研究中,应考虑进行成本效益分析以评估新型心血管风险评估策略。